IMF Videos Search Content For Healthcare Professional (166) Healthcare Provider (165) Care Partner (128) Patient (128) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (259) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Does SARS-CoV-2 Vaccination Impact the Risk of Progression from MGUS to MM? December 16, 2022 ASH Real-world Outcomes for Patients Treated with Ide-Cel after having Previously Received a BCMA-Targeted Therapy December 16, 2022 ASH Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The iStopMM Study December 15, 2022 ASH Effects of Arginine Deprivation to Proteasome Inhibitor Resistance in Multiple Myeloma December 15, 2022 ASH Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age December 15, 2022 ASH Association of Socioeconomic Status with Adherence, Progression Free and Overall Survival to Oral Agents in Multiple Myeloma Patients December 13, 2022 ASH MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma? December 13, 2022 ASH Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment January 27, 2022 ASH Updates on the Binding Site's ongoing collaboration with the iStopMM study January 27, 2022 ASH Screening for Monoclonal Gammopathy of Undetermined Significance: First Results from the iStopMM Study January 26, 2022 ASH DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma January 6, 2022 ASH Impact of Chromosome 1 Abnormalities Among Patients with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis from the ENDURANCE Trial January 6, 2022 ASH Load More
